---
title: Target RWE Inflammatory Bowel Disease Research Presented at UEG Week 2021
description: >-
  Read the latest news on regulatory-grade real-world evidence: Target RWE
  Inflammatory Bowel Disease Research Presented at UEG Week 2021.
date: '2021-10-11'
category: News
tags:
  - Conference Presentation
  - R&D
  - Care
  - Gastroenterology
  - IBD
canonical_url: >-
  https://www.pedestalhealth.com/resources/news/conference-presentation/target-rwe-inflammatory-bowel-disease-research-presented-at-ueg-week-2021/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: target-rwe-inflammatory-bowel-disease-research-presented-at-ueg-week-2021
id: XgKvaRG8W9NM7Wrd0uIgC
contentType: article
---

Target RWE participated in the virtual United European Gastroenterology [(UEG) Week](https://ueg.eu/week) in October 2021 to share new real-world data findings from a recent TARGET-IBD poster- *Histological Inflammation Predicts Loss of Remission Among Crohn’s Patients with Endoscopic Remission: A US Cohort Analysis*.

The TARGET-IBD analysis focused on assessing the associations between clinical characteristics and loss of remission (LOR) in a real-world US-based cohort of Crohn’s disease (CD) patients in endoscopic remission. The analysis found that 53.8% of patients experienced LOR during follow-up to second colonoscopy. In addition, ileal disease at index was significantly associated with future LOR compared to isolated colonic disease. Furthermore, evidence of histologic inflammation was associated with twice the odds of LOR and was a predictor of subsequent LOR.

“The findings presented at UEG Week highlight the need for future research to be more focused on determining if treatment modification or intensification is effective at preventing LOR in patients with risk factors,” said Julie M. Crawford, MD, Senior Director of Scientific and Medical Affairs.

[TARGET-IBD](https://www.targetrwe.com/services/data-solutions/registries/inflammatory-bowel-disease-ibd/) is an active 5-year longitudinal, observational study of more than 4,600 adult and pediatric patients with IBD receiving usual care from 36 academic and community centers throughout the U.S. Real-world data is collected retrospectively for three years from the time of the patient's date of consent and patients are also followed prospectively for a minimum of five years. The robust TARGET-IBD cohort allows for the collection of effectiveness and safety data upon new drug approvals.

Learn more about Target RWE’s publications [here](https://www.targetrwe.com/research/publications/).